Clinical opinions and case studies on understanding and managing hypogammaglobulinaemia in multiple sclerosis: United Kingdom perspective
Hypogammaglobulinaemia and prolonged or substantial reductions in immunoglobulin levels carry clinical implications for people living with MS. UK healthcare professionals working in MS can learn from other immunological specialities concerning the management of infection, vaccination, immunisation and treatment with different DMTs. They should be aware of how hypogammaglobulinaemia in MS presents and how to manage this in the context of DMTs, including the interpretation of haematological parameters and safety.
Authors
- Sharmilee Gnanapavan (ORCID: https://orcid.org/0000-0003-2817-9922)
- Angray S. Kang (ORCID: https://orcid.org/0000-0002-4672-4114)
- Gavin Giovanonni
- David A. Baker (ORCID: https://orcid.org/0000-0001-7896-6217)
Institutions
- Queen Mary University of London (GB)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1016/j.msard.2025.106353
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharmaceuticals UK Limited